From explains apartments near university of minnesota twin cities broadband communicationsinfrastructure, metrodome draws enterprise mobility and public safety solutions tohigh-definition video and mobile devices, Motorola is leading the next wave ofinnovations that enable people, enterprises and governments to be moreconnected and more mobile Motorola (NYSE: MOT) had sales of US $30.1 billionin 2008. For more information, visit and the stylized M Logo are registered in the US Patent & TrademarkOffice. All other product or service names are the property of theirrespective owners (C) Motorola, Inc 2009. All rights reserved.Media Contact:Kristine MulfordMotorolaOffice: +1 847-576-4506mailto:SOURCEMotorolaKristine Mulford of Motorola, +1-847-576-4506, .
Alliance One International, Inc baseball managers . Updates Early Results of Its Tender Offer andConsent SolicitationMORRISVILLE, N.C., June 25 /PRNewswire-FirstCall/ -- Alliance OneInternational, Inc minnesota twins . Forward Looking Statements This press release contains forward-looking statements.Actual results maydiffer materially from those reflected in the forward-looking statements.Additional information concerning factors that could cause actual results todiffer materially from those in the forward-looking statements is containedunder the heading of Risk Factors listed from time to time in the Company'sfilings with the Securities and Exchange Commission, including its AnnualReport on Form 10-K for the fiscal year ended March 31, 2009, filed on June 8,2009 twin babies clothes . About Alliance OneAlliance One is a leading independent leaf tobacco merchant serving theworld's large multinational cigarette manufacturers twin babies clothing . One International, Inc.Joel Thomas, Vice President -- Treasurer, Alliance One International, Inc.,+1-919-379-4300. CINCINNATI, OH, Jun 25 (MARKET WIRE) -- Akebia Therapeutics, Inc., a discovery and development company focused onanemia and vascular disorders, today announced the appointment of Ian A.W.
Howes to the position of chief financial officer and vice president,corporate development Mr baseball tickets . Howes will serve as a member of Akebia'ssenior management team, and brings extensive finance, businessdevelopment and operational experience to the company."We are extremely pleased to have Ian join Akebia twin babies gifts . He brings a wealth ofsenior level financial and corporate development experience and leadershipto the company twin babies products . We have a number of very exciting programs underway andIan's experience in capital management, corporate development andoperations will be essential in helping the company successfully move intoour next phase of value creation," said Dr metrodome . Joseph Gardner, president andchief executive officer at Akebia."I am excited to be joining a company with such clearly differentiatedproducts which are potential breakthrough new therapies and treatments forpatients with anemia, vascular disorders, wound healing and cancer," saidMr Howes. "Akebia is expecting important near-term milestones includingmoving its first product into the clinic for anemia and preparing topublish groundbreaking preclinical results for an additional program,making this a particularly exciting time to join the company."Mr.
Howes joins Akebia from Serenex, Inc., where he held the position ofchief financial officer and senior vice president, corporate development.In this position, Mr joe mauer . Howes was responsible for generating over $75million in private equity and debt capital and managing the sale of thecompany to Pfizer, Inc Prior to that, Mr minnesota twins . Howes was chief financialofficer and vice president, operations at Paradigm Genetics, Inc.About Akebia TherapeuticsAkebia Therapeutics is a discovery and development company focused onanemia and vascular disorders twin babies clothes . An IND for Akebia's lead program, AKB-6548,an orally bioavailable HIF- prolyl hydroxylase (HIFPH) inhibitor forpatients with anemia, is scheduled to be filed in July 2009.The market for chronic anemia drugs, which generates over $10 billion inworldwide sales, is dominated by injectable forms of the recombinantprotein growth factor EPO . There are currently no orally dosed smallmolecule drugs for chronic anemia. AKB-6548 potentially promises to be asafer, less expensive, orally dosed pharmaceutical to stimulate endogenousEPO production. Additionally, Akebia has a novel HPTP beta inhibitor,AKB-9778, for the treatment of vascular leak syndromes and peripheralartery disease which will commence phase 1 clinical trials in mid-2010.Website: HowesCFO & V.P.
Comments are closed.